Models for time-varying covariates in population pharmacokinetic- pharmacodynamic analysis

British Journal of Clinical Pharmacology

Volumn 58, Issue 4, 2004, Pages 367-377

  Wählby, Ulrika ^a,d   Thomson, Alison H ^b   Milligan, Peter A ^c   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Covariate; NONMEM; Time varying

Indexed keywords

BILIRUBIN; GENTAMICIN; PACLITAXEL; PEFLOXACIN; VORICONAZOLE;

ARTICLE; BODY SURFACE; BODY WEIGHT; COVARIANCE; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; INDIVIDUALIZATION; MATHEMATICAL ANALYSIS; MODEL; POPULATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

GENTAMICINS; HUMANS; MODELS, CHEMICAL; PEFLOXACIN; PHARMACOKINETICS; PHARMACOLOGY; PYRIMIDINES; REGRESSION ANALYSIS; TIME FACTORS; TRIAZOLES;

EID: 4744351347     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02170.x     Document Type: Article

References (22)

1. Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 2000; 50 (2): 125-34.
2. Anderson BJ, van Lingen RA, Hansen TG, Lin Y-C, Holford NH. Acetominophen developmental pharmacokinetics in premature neonates and infants. Anesthesiology 2002; 96 (6): 1336-45.
3. van den Anker JN. Pharmacokinetics and renal function in preterm infants. Acta Paediatr 1996; 85 (12): 1393-9.
4. Tornatore KM, Reed KA, Venuto RC. Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. Ann Pharmacother 1995; 29 (2): 120-4.
5. Fukatsu S, Yano I, Igarashi T, Hashida T, Takayanagi K, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 2001; 57 (6-7): 479-84.
6. Yates CR, Vysokanov A, Mukherjee A, Ludden TM, Tolley E, Meduri GU, Dalton JT. Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. J Clin Pharmacol 2001; 41 (4): 415-24.
7. Taright N, Mentré F, Mallet A. Non-stationarity of kinetic parameters in multi-occasion designs. Oral Presentation, Sixth PAGE Meeting, Glasgow 1997.
8. Holford NHG, Bååthe S, Karlsson MO. Auckland bones and summer sun. Oral Presentation, Tenth PAGE Meeting, Basel 2001.
9. Beal SL, Sheiner LB. NONMEM Users Guides. San Francisco, CA: University of California, 1992.
10. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokin Biopharm 1993; 21 (6): 735-50.
11. Wählby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2001; 28 (3): 231-52.
12. Wählby U, Bouw MR, Jonsson EN, Karlsson MO. Assessment of type i error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn 2002; 29 (3): 251-69.
13. Rosario MC, Thomson AH, Jodrell DI, Sharp CA, Elliott HL Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol 1998; 46 (3): 229-36.
14. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48 (6): 2166-72.
15. Karlsson MO, Jonsson EN, Wiltse CG, Wade JR. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokin Biopharm 1998; 26 (2): 207-46.
16. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20 (24): 4713-21.
17. Sadray S, Jonsson EN, Karlsson MO. Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection. Pharm Res 1999; 16 (8): 1260-5.
18. Higgins KM, Davidian M, Giltinan DM. A two-step approach to measurement error in time-dependent covariates in nonlinear mixed-effects models, with application to IGF-I pharmacokinetics. J Am Statist Assoc 1997; 92 (438): 436-48.
19. Mould DR, Holford NH, Schellens JH, Beijnen JH, Hutson PR, Rosing H, ten Bokkel Huinink WW, Rowinsky EK, Schiller JH, Russo M, Ross G. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 2002; 71 (5): 334-48.
20. Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167 (1): 173-9.
21. Jaresko GS, Boucher BA, Dole EJ, Tolley EA, Fabian TC. Risk of renal dysfunction in critically ill trauma patients receiving aminoglycosides. Clin Pharm 1989; 8 (1):43-8.
22. Fattinger KE, Verotta D, Porchet HC, Munafo A, Le Cotonnec JY, Sheiner LB. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. Am J Physiol 1996; 271 (4 Part 1): E775-87.